A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma.

Muhammad Shaalan Beg,Hao Zhu,David Hsieh,Syed Mohammad Ali Kazmi,Aravind Sanjeevaiah,Amit G. Singal,Radhika Kainthla,Leticia Khosama,Kimberli Crane,Rolf A. Brekken,Adam C. Yopp

A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab, in combination with pembrolizumab in patients with advanced hepatocellular carcinoma.

2020

Muhammad Shaalan Beg
Hao Zhu
David Hsieh
Syed Mohammad Ali Kazmi
Aravind Sanjeevaiah
Amit G. Singal
Radhika Kainthla
Leticia Khosama
Kimberli Crane
Rolf A. Brekken
Adam C. Yopp

TPS599Background: Phosphatidylserine (PS) is an immunosuppressive lipid segregated to the inner leaflet of the plasma membrane of normal cells. PS is externalized to the outer leaflet of the plasma...

Keywords:

Bavituximab
Antibody
Hepatocellular carcinoma
Pembrolizumab
Internal medicine
Phosphatidylserine
Clinical trial
Medicine
Oncology
Pathology
in patient
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations